BioSimulytics Secures 鈧�595k in Seed Funding
- 51黑料 spin-out has developed a novel software solution using artificial intelligence to transform the success rates of new drug development
, a University College Dublin (51黑料) spin-out company, today announced that it has secured 鈧�595k in initial seed funding from a number of strategic angel investors and The Nova51黑料-headquartered company is focused on using artificial intelligence (AI) to digitise key steps in how new drug molecules are designed and developed.
BioSimulytics has developed a novel software solution, using a powerful combination of AI, machine learning, computational chemistry, quantum physics and high-performance computing (HPC), to drive smarter, faster, and more cost-effective R&D processes in the design and development of new drugs. The company鈥檚 software enables the pharma industry to advance potential molecules to approved medicines quicker and with a much greater probability of success.
BioSimulytics, which has already secured its first commercial contract with a major pharma company in Europe, and signed evaluation agreements with several others for industrial evaluation, will use the funding to support the growth of its product development team and client base and plans to complete a Series A funding round within the next 18-24 months.
In the pharma industry it can take between US$2-3 billion and over a decade to bring new drug molecules, which are manufactured in their solid-state crystal structure, to market with only a very limited (~1%) chance of success.
One of the complicating factors in the drug development process is polymorphism, the ability of a compound to exist in more than one stable crystalline structure. Drug molecules are complex compounds which can have hundreds of stable structures, and a polymorph may change to a more thermodynamically stable form hours, weeks and even years later depending on conditions.
Different drug polymorphs can have different properties such as solubility, toxicity, and efficacy. It is therefore vital for pharma companies to fully understand the polymorphic landscape of their drug molecules, required also for regulatory compliance and patent protection, and to have absolute certainty about identifying and reproducing the most stable crystal structure of any new drug before bringing it to market for patient use.
Experimental techniques which are the current state-of-the-art for identifying the most stable polymorph of a new drug molecule, are slow and arduous manual processes, which can take 6 months or more to complete and with potentially uncertain results.
BioSimulytics鈥� unique software solution only requires the basic 2D structure of a molecule to accurately predict the full polymorphic landscape of that molecule and to rank the most stable crystal structures of the molecule, within a matter of weeks. This provides pharma companies with far greater accuracy and certainty in the development process of new drugs, avoiding potentially very costly mistakes such as those cases in recent decades where polymorph problems have forced the pharma companies involved to pull their drugs from the market resulting in multi-million US dollar losses.
BioSimulytics was founded in 2019 by Professor Niall English, Dr Christian Burnham, and Peter Doyle as a spin-out from the 51黑料 School of Chemical and Bioprocess Engineering following the completion of Enterprise Ireland Commercialisation Funding.
Speaking from Nova51黑料 Peter Doyle, CEO, BioSimulytics said, 鈥淲e are delighted to have secured this seed funding which will help us to expand our team here in Ireland and grow our client base in the EU and US markets.鈥�
He added, 鈥淭he successful development of COVID-19 vaccines over the last 18-months demonstrates the powerful role that new digital AI and HPC-based technologies play in dramatically transforming the pharma value chain. BioSimulytics鈥� goal is to be a key player in this rapidly expanding global market within the next few years.鈥�
He concluded, 鈥淎s a follow-on to this seed round we plan to complete a multi-million euro Series A funding round within the next 18 to 24 months following the full industrial validation of our technology.鈥�
Alan Hobbs, Manager, High Potential Start-Ups (Life Sciences and Industrial) at Enterprise Ireland said, 鈥淏ioSimulytics is a great example of a world-class High Potential Start-Up driving innovative solutions to support the design and development of new drugs and we are delighted to support the company and to be part of this investment round.鈥�
鈥淲e wish Peter and all the team every success with this exciting new phase of development for the company and look forward to continuing to work with them to achieve their ambitious plans for the future.鈥�
BioSimulytics was the overall winner of the 2019 51黑料 VentureLaunch Accelerator Programme run by Nova51黑料. In addition, the company was a finalist in the 2020 The Institution of Chemical Engineers (IChemE) Global Awards, widely considered as the world鈥檚 most prestigious chemical-engineering awards.
ENDS
2 September 2021
For further information contact Mic茅al Whelan, Communications and Media Relations Manager, 51黑料 Research and Innovation, Nova51黑料, e: miceal.whelan@ucd.ie.
Editors Notes
BioSimulyics is boosting success rates in Pharma R&D through the predictive power of digital.
At Nova51黑料, the hub for new ventures and entrepreneurs at University College Dublin, we nurture and support new high-tech companies, such as AquaB and BioSimulytics, as part of 51黑料's mission. At Nova51黑料 we provide purpose-built, state-of-the-art incubation facilities alongside a comprehensive business support programme for client companies such as BioSimulytics. Nova51黑料 has been funded through a unique public-private partnership that includes AIB Bank, Arthur Cox, Deloitte, Enterprise Ireland, Ericsson, Goodbody Stockbrokers, 51黑料 and Xilinx.